Cytori Strengthens Global Intellectual Property Portfolio With Key Patents
Published: Nov 16, 2016
SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics, Inc. (NASDAQ: CYTX) (“Cytori” or the “Company”) announced today the issuance of a number of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has over 90 global patents issued and another 55 patent applications pending around the globe. Several of Cytori’s recently-issued patents contain claims providing protections for Cytori’s program in the use of Cytori Cell Therapy™ for treating scleroderma. Cytori recently completed enrollment in its STAR approval trial in the US for this indication.
“The recent patents specifically serve to support our current development efforts in scleroderma, osteoarthritis, and burn.”
On November 1, 2016, US Patent No. 9480718 was issued. This patent contains claims applying to the use of adipose derived cells to treat peripheral vascular diseases (“PVD”), which are blood circulation disorders that affect the blood carrying vessels of the body that can narrow, experience spasm or become blocked. PVD is often a contributory process in scleroderma. This patent has term at least through 2022 and claims the use of Cytori Cell Therapy™ for PVD, including but not limited to PVD associated with scleroderma.
On November 8, 2016, US Patent No. 9486484 was issued. This patent provides protections around the use of adipose-derived cells for the treatment of edema. Edema, also known as ‘swelling’, is often accompanied by increased blood flow and is a very common secondary clinical manifestation of numerous inflammatory and immune-related conditions. Specifically, edema contributes directly to the diminished hand dysfunction found often in the acute phases of scleroderma. The ‘484 patent term lasts through at least 2029.
Other recently issued patents strengthen Cytori’s osteoarthritis program. Last month, US Patent No. 9463203 was issued. The ‘203 patent protects the use of adipose-derived cells for treating cartilage defects, including but not limited to osteoarthritic defects, defects in the articular cartilage and defects in meniscus. Earlier this year, Cytori completed the ACT-OA clinical trial, a phase IIb trial assessing the use of adipose-derived cells for the treatment of osteoarthritis of the knee. The ‘203 patent term lasts through at least 2022.
The European Patent Office also recently issued European Patent No. EP2617427 to Cytori. The ‘427 Patent protects the use of adipose-derived cells for restoring tears in cartilage such as those present in osteoarthritic joints, and has a patent term at least through 2024.
On November 15, 2016 US Patent No. 9492483 was issued. The ‘483 Patent relates to the use of adipose-derived regenerative cells for the treatment of burn, and area in which Cytori has had an active research program for several years in conjunction with the US Government. The ‘483 patent term lasts at least through December 2022.
“Cytori has amassed a large global intellectual property position and continues to expand and strengthen the portfolio through internal R&D efforts and targeted in-licensing,” noted John D. Harris, Vice President and General Manager, Cell Therapy. “The recent patents specifically serve to support our current development efforts in scleroderma, osteoarthritis, and burn.”
Cytori Therapeutics is a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefit across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. For more information: visit www.cytori.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements that involve known and unknown risks and uncertainties. All statements, other than historical facts are forward looking statements. Such statements, including statements regarding projected patent terms, and potential uses of Cytori’s patent portfolio to support its product pipeline, are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include risks related to protection and enforcement of our intellectual property portfolio such as risks regarding infringing or competing third party intellectual property, risks that our intellectual property may infringe other intellectual property rights (or may be at risk of challenge or invalidation), or risks that the claims in our patents and patent applications may be insufficient in coverage or scope to support and achieve our corporate objectives, and other risks and uncertainties described under the "Risk Factors" in Cytori’s Securities and Exchange Commission Filings, included in our annual and quarterly reports.
There may be events in the future that we are unable to predict, or over which we have no control, and our business, financial condition, results of operations and prospects may change in the future. We assume no responsibility to update or revise any forward- looking statements to reflect events, trends or circumstances after the date they are made unless we have an obligation under U.S. Federal securities.
Tiago Girao, +1 858-458-0900